Effect of alprostadil on serum bone morphogenetic protein 7 and transforming growth factor-β1 in patients with diabetic nephropathy

Objective To investigate the clinical efficacy of alprostadil in the treatment of diabetic nephropathy, and its effect on serum bone morphogenetic protein 7(BMP-7)and transforming growth factor-β1(TGF-β1)levels in patients. Methods From January 2014 to January 2016, 120 cases of diabetic nephropathy in the People's Hospital of Beilun District were selected in the study.According to different treatment methods, the patients were divided into study group and control group, with 60 cases in each group.The two groups were treated with basic treatment, the study group was treated with alprostadil for 8 weeks.The clinical efficacy and serum levels of BMP-7 and TGF-β1 were compared between the two groups. Results There were no significant differences in serum BMP-7 and TGF-β1 between the two groups before treatment(P>0.05). After treatment, the serum BMP-7[(17.54±3.90)pg/mL]in the study group was higher than that in the control group[(15.20±2.96)pg/mL](t=3.607, P 0.05). After treatment, the levels of UAER, Hcy, Scr, BUN in the study group were(89.62±17.74)g/min, (23.55±4.17)mol/L, (64.2±8.5)mol/L, (6.70±0.96)mmol/L, which were significantly lower than those in the control group[(118.50±21.18)g/min, (29.69±4.82)mol/L, (74.7±9)mol/L, (7.52±0.89)mmol/L](t=8.097, 7.462, 6.57, 4.852, all P<0.05). Conclusion Alprostadil has better clinical effect on diabetic nephropathy, and can significantly improve serum BMP-7 and TGF-β1 levels. Key words: Diabetic nephropathy; Bone morphogenetic protein-7; Transforming growth factor beta 1; Alprostadil